Efgartigimod Delivers Sustained Long-Term Benefit in Myositis, Sjogren's Disease
ARGX sits 57% above its 52-week low of $510.055.
Summary
ARGENX presented new positive clinical data for its drug efgartigimod (VYVGART) at EULAR 2026, showing long-term sustained patient benefit in myositis and Sjogren's disease. Data from open-label extension studies (ALKIVIA+ and RHO+) indicated consistent safety and clinically meaningful improvements, with 37.5% of myositis patients maintaining major improvement at 52 weeks. This reinforces the drug's efficacy and safety profile, potentially expanding its market opportunity in autoimmune diseases. This follows a period of strong financial results and an expanded FDA label for VYVGART. Topline results from the Phase 3 ALKIVIA study for myositis are expected in the third quarter of 2026.
At the time of this announcement, ARGX was trading at $802.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.7B. The 52-week trading range was $510.06 to $934.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.